W hat is automation? Automation allows screening to be performed as a high throughput science. While it is basically stringing a series of mechanical devices together to perform a scheduled series of tasks, without this technique our science of HTS would not exist. Over the ten years since it has been recognized, however, this field has undergone rapid continuing evolution. The challenge has always been to attain a faster, cheaper and smaller technological level. Screening is currently being performed routinely in 96, 384 and 1536 well formats. The majority of the automation has been developed to handle the first two formats, since 1536 is dense enough to present very specific problems.
Most of us have a series of preferred automation companies, who for various reasons have become the companies of choice. The cost of this type of equipment often precludes comparisons between differing types of automation, and once a company has purchased from a vendor, changing to an alternate vendor often proves difficult. A smoothly running screening facility should operate similarly to a manufacturing process. Although this makes the introduction of novel ideas difficult, without disruption of the workflow it is a necessary evil in order to reach the goal of faster, cheaper and smaller. With the current need for miniaturization some types of automation equipment have the potential for being out of date within a year, which causes the purchasing of new equipment to become a toss-up. Do we buy now or wait a year for the latest? Some manufacturers have been able to design equipment that is sufficiently flexible to allow for rapid updating to new requirements. On the whole, these have proved to be companies who have close ties to the screening environment and who have flexible development teams.
Large laboratories are able to dedicate equipment for specific assay types. However, most of the smaller facilities must maximize their equipment and make it flexible enough to swap assay types within a short time frame. This creates a challenge to overcome some of these "road blocks" in a functioning HTS facility. Many HTS groups are not large enough to support a development group, but they have the vision for a novel way to solve their difficulties and a desire to explore their ideas. Given a truly novel idea, the most cost effective way to do this is to find a manufacturing company who is willing to co-develop the hard-ware and proceed from there.
The smaller facilities must use "creative" methods to become as efficient as their larger, more affluent competitors. One example of these "creative" methods originated in the early 1990s with the engineers who were developing the first multitasking laboratory robotic systems. Zymark and others developed lines of robotic systems that were capable of multitasking using various assay formats. Beckman/Sagian chose a similar route but developed a software system which allowed for both the addition of almost any instrument to the ORCA linear system, and its scheduling into a robotic assay format. The use of this creativity extends beyond the transfer of one piece of equipment for another -it extends to the application of one technology to another novel application. Some examples of this are as follows: the use of ink jet technology as used in printers to the reapplication in the Cartesian PixSys SQ system enabling accurate liquid transfers to be performed in a 1536 format, and the use of peristaltic pump technology by the Labsystems Multidrop allowing accurate, fast 384 automated liquid transfer. The use of pins to transfer viral plaques onto arrays during the development of the Human Genome project stimulated development of a tool capable of transfer of submicroliter liquid volumes. Development proceeded on two fronts -Biosys in England developed a workstation gridding system and Beckman Coulter developed a 96 well pin tool for use with the Biomek 2000. Further development in our laboratory by a team led by David Brandt enabled the Biosys Biogrid to be adapted for new chemical entity (NCE) transfer in DMSO from a 96 to a 384 format. This was achieved by the use of specially machined pins and has enabled the technology to be used reliably in our routine screening process. The use of pin transfer in an automated fashion always raises concerns about the possibility of cross contamination of the source compound plates. The wash steps, which automatically follow each compound transfer, have been monitored for contamination and no compound was detected by LC/MS in the end washing fluid. The pins must be dry before proceeding to the next compound plate and this can be done robotically by exposure to a fan for 15-30 seconds.
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All of these steps are available on the Biomek 2000 and FX systems and we have used the 0.015" Beckman pins to perform low nanoliter transfers into 384 half well assay plates. Currently we use the Acme-Automation 0.20" pins for compound transfer from our 384 library, and naturally we keep our library plates with equivalent depths of solubilized compound to prevent errors.
The above diagram depicts the variation found in the dispense volumes when using pin tools for reformatting from 96 well to a 384 well format. As can be seen there is clearly an improvement by the use of the smaller pins but for many applications the larger pins are adequate.
The table above of pins from various sources, which outlines the routine performance in our hands, clearly demonstrates that nL volume transfers by pin tools are reproducible and that reliability is not pin dependant. The difference in volume transfer of the larger size pins has not been further investigated since we do not use any pin tool over 0.030" for routine assay applications.
As can be seen, the advantages gained from the reapplication of this technology into the screening field has enabled us to conserve our most valuable resource -the NCE library. An added bonus has been the decrease in cost for disposables and reagents.
Where do we need to go next? The most pressing need is for very accurate, fast and realistically priced detection units. The rush to smaller volumes has increased the sensitivity required by detection systems, which has forced detection technology towards CCD cameras. These are, at the present time, beyond the budget of many screening units and are not developed sufficiently to be reliable enough for long-term routine use. Other forms of detection, such as CZE, have not been incorporated into HTS for technical reasons but there could be a place for them as an alternate detection system. Novel technologies will have to be developed for use with genomic screening and there is a large market available for any company willing to plunge into the unknown.
The last, but possibly the most important, area for "creative" development is in the training and education of laboratory personnel. The pool of trained personnel available for HTS is small and there are very few courses taught in this discipline. Creative ideas are needed to encourage development of training courses and recruiting policies, which result in the retention of highly motivated screeners.
I hope that the challenges put forward in this presentation encourage some "out-of-the box" thinking, which will result in cooperation between manufacturers and screeners and ultimately benefit us all.
I would like to acknowledge all the screeners in the High Throughput Screening Facility of Procter and Gamble Pharmaceuticals who do think "out of the box" and who do challenge the engineering staff to include novel technologies to enable the screens to run better, faster and cheaper.
